Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Astal Laboratories has submitted copies of newspaper publications containing its unaudited standalone financial results for the quarter ended 31 December 2025, as required under SEBI LODR Regulation 47. The results were published in The Financial Express and Jansatta (Delhi edition) on 15 February 2026, and in The Business Standard (Hyderabad edition) on 16 February 2026. For Q3 FY26, revenue from operations jumped to Rs. 5,223.53 lakhs, up sharply from Rs. 1,445.88 lakhs in the same quarter last year. Total revenue for the quarter stood at Rs. 5,227.18 lakhs, with PBT of Rs. 313.10 lakhs and PAT of Rs. 235.73 lakhs, slightly lower than the Rs. 248.85 lakhs PAT posted in Q3 FY25. For the nine months ended 31 December 2025, total revenue reached Rs. 11,520.36 lakhs and PAT came in at Rs. 702.96 lakhs, up from Rs. 618.05 lakhs a year earlier. Basic EPS for the quarter was Rs. 8.28 and diluted EPS was Rs. 5.27.
This is a routine regulatory compliance filing, so it is unlikely to move the stock on its own. However, the strong revenue growth in Q3 (roughly 3.6x year-on-year) is a positive signal for the business, though margins appear to have compressed as profit growth lagged revenue growth. Shareholders should look at the full results and management commentary for clarity on the sustainability of this revenue surge.